Atopic Dermatitis Clinical Trials in San Diego, California

10 recruitingSan Diego, California

Showing 110 of 10 trials

Recruiting

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Atopic Dermatitis
Sanofi1,000 enrolled43 locationsNCT07290803
Recruiting
Phase 2

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis (AD)
Enveda Therapeutics60 enrolled17 locationsNCT07298395
Recruiting
Phase 3

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Atopic Dermatitis
Organon and Co180 enrolled48 locationsNCT07265479
Recruiting
Phase 3

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Atopic Dermatitis
AbbVie200 enrolled124 locationsNCT06389136
Recruiting
Phase 3

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Atopic Dermatitis
Pfizer500 enrolled31 locationsNCT06807281
Recruiting
Phase 2

A Study Evaluating TRIV-509 in Atopic Dermatitis

Atopic Dermatitis
Triveni Bio90 enrolled44 locationsNCT07167758
Recruiting
Phase 3

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis
LEO Pharma195 enrolled72 locationsNCT06311682
Recruiting
Phase 1

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Atopic Dermatitis
National Institute of Allergy and Infectious Diseases (NIAID)86 enrolled8 locationsNCT06504160
Recruiting
Phase 2

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Atopic Dermatitis
Pfizer340 enrolled97 locationsNCT05995964
Recruiting
Phase 2

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

Atopic Dermatitis (AD)
CAGE Bio Inc.180 enrolled16 locationsNCT06810050